Table II.

Incremental cost-effectiveness ratios (ICERs) under various survival benefits for GCB and ABC DLBCL patients.

HR		GEP		IHC using Hans algorithm
GCB	ABC	Subtype-based treatment a	Novel treatment b	Subtype-based treatment	Novel treatment
0.95	0.9	118,759	246,747	117,193	242,535
	0.8	56,017	246,747	57,487	193,286
	0.7	35,719	246,747	37,235	157,201
	0.4	15,478	246,747	16,373	95,938
0.9	0.9	dominated c	119,725 c	108,916	135,978
	0.8	56,017	122,254	55,387	118,923
	0.7	35,719	122,254	36,327	104,081
	0.4	15,478	122,254	16,186	73,051
0.8	0.9	dominated	81,493 c	dominated	81,493 c
	0.8	56,017	59,465	51,453	66,079
	0.7	35,719	59,465	34,570	61,191
	0.4	15,478	59,465	15,809	48,842
0.7	0.9	dominated	61,067 c	dominated	61,067 c
	0.8	dominated	46,375 c	dominated	46,375 c
	0.7	35,719	38,542	32,878	42,722
	0.4	15,478	38,542	15,425	36,259
0.5	0.5	19,487	21,690	18,009	23,923
	0.4	15,478	21,690	14,692	23,078
0.4	0.4	15,478	17,476	14,331	19,235

GCB, germinal center B-cell-like, ABC, activated B-cell-like; IHC, immunohistochemistry; GEP, gene expression profiling.

^aICER of subtype-based treatment compared with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment.

^bICER of novel treatment compared with subtype-based treatment.

^cWhen subtype-based treatment was dominated, the ICER of novel treatment was calculated by comparing to RCHOP treatment.